Galapagos (GLPG) to Release Quarterly Earnings on Wednesday

Galapagos (NASDAQ:GLPG) will likely be releasing its earnings data after the market closes on Wednesday, April 23rd. Analysts expect Galapagos to post earnings of ($0.19) per share and revenue of $72.22 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Galapagos Stock Up 0.7 %

Shares of NASDAQ:GLPG opened at $24.66 on Monday. The company has a 50 day moving average of $25.37 and a two-hundred day moving average of $26.30. Galapagos has a 52-week low of $22.36 and a 52-week high of $31.23.

Analyst Ratings Changes

A number of brokerages have commented on GLPG. Barclays reiterated an “underweight” rating on shares of Galapagos in a report on Thursday, January 23rd. Morgan Stanley lowered Galapagos from an “equal weight” rating to an “underweight” rating and lowered their price objective for the company from $31.00 to $22.00 in a research note on Friday, February 14th. Finally, TD Cowen lowered Galapagos from a “strong-buy” rating to a “strong sell” rating in a research report on Thursday, January 9th. Four equities research analysts have rated the stock with a sell rating and four have given a hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $25.33.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.